Assessment of HER2 status in breast cancer: why, when and how?
about
ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancerMolecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast CancerHER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologistsFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentFrom oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesionsOut of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinomaThe epidermal growth factor receptor family in breast cancer.Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigensAn innovative method for obtaining consistent images and quantification of histochemically stained specimens.Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography.Radiolabeling of HER2 specific Affibody(R) molecule with F-18.Regulation of transcription by synthetic DNA-bending agents.Variation of the prognostic significance of HER-2 expression in breast cancer according to tumor size.Cyclic GMP-dependent protein kinase regulates CCAAT enhancer-binding protein beta functions through inhibition of glycogen synthase kinase-3.ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients.Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab.A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer.
P2860
Q24810389-34311AD0-22F2-4839-94FE-296E6E8A7EBEQ28072513-D1EF9683-CB71-4681-8DDA-62C914522AD2Q28078111-7ED30FB0-3235-4EFC-B3E0-84F5717DC22CQ28533949-4D40EF6A-D247-4375-8038-0075083B4DAAQ30168082-0AD99539-B450-49FA-8358-F732CC93C5D4Q33562282-71D0AEDA-32D9-4128-AB67-3A9F08FE003DQ34064466-55EE6642-DDCE-4A62-AC7B-EF61A934C2B8Q34363400-B4443C41-396F-48FB-9D4D-D0814EFDA267Q35123700-91E45EF6-491D-4941-B1EB-0B474EEDF15AQ35540913-4B527F4E-82BA-4345-8357-7CA440E22296Q35789663-91605AB4-4F4E-4BE2-8485-E38CBC770575Q36627997-9E079C0F-9910-4626-ACA0-87FAF141665CQ37071060-7E521F60-71B4-400E-A169-6EDEF76B4030Q38309182-51B85B5A-8821-46BD-BCE2-3316D9B438BEQ38453306-DC6C566E-25D4-4C5A-A5A6-6BD14D79F411Q40390914-18481FAB-4445-46F8-89C2-E86B205CE729Q40634215-64D4D53C-6BD9-4E48-B1C3-5412A0B55EECQ45251536-7533B369-08DE-4288-A609-C6F257327637Q45782977-ED1212F6-4AB7-43A8-A8C2-5D1A7F7B283D
P2860
Assessment of HER2 status in breast cancer: why, when and how?
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Assessment of HER2 status in breast cancer: why, when and how?
@ast
Assessment of HER2 status in breast cancer: why, when and how?
@en
type
label
Assessment of HER2 status in breast cancer: why, when and how?
@ast
Assessment of HER2 status in breast cancer: why, when and how?
@en
prefLabel
Assessment of HER2 status in breast cancer: why, when and how?
@ast
Assessment of HER2 status in breast cancer: why, when and how?
@en
P2093
P1476
Assessment of HER2 status in breast cancer: why, when and how?
@en
P2093
P304
P356
10.1016/S0959-8049(99)00264-6
P50
P577
2000-01-01T00:00:00Z